A S CL!N!C!ANS, WE ARE FACED WITH A LARGE BODY OF lite rature conceming the clinical evaluatio n of 'newer' medical therapies. In recent years, multiple pharmacological agents, including immunosuppress ives, new de live ry systems for aminosalicylic acid (5-ASA), more potent corticosteroids, and misce llaneous therapies, such as metronidazolc and nutritional therapy, have been evaluated for inflammatory bowel disease ( 1 ). The results of trials evaluating these therapies are often equivocal, sometimes conflicting, and thus difficult to interpret. Extrapo lating the results of positive clinical trials to patients in practice is not always easy (2). The reality of our limited health care resources have brought economic factors into consideration when evalua ting medical or surgical therapy. More and more the question to be answered is not what is the most efficacious therapy, but rather which therapy wi ll provide the best clinical outcome for the dollars s/Jent. This means that in addition to trying to decide if the results of a trial are clin ically significa nt, we must also consider whether the increased costs that a re often involved with new therapies warrant their use over less expensive (and perhaps slightly less efficacious) ones. In this light, decision analyses and cost-effective analyses are now flourishing. Neither has yet to be applied to the manageme nt of inflammatory bowel disease.
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A more critical appraisal of the published reports is essential to better apply their results to 
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The quality of clinical trials has come under greater scrutiny in recent years. Scoring systems, such as t he one developed by C halme rs et al (3 ) , provide a for mal evaluation of the quality of reported clinical trials. T his system assesses a clinical trial on the basis of design (eg, blind ing, patient selection, use of placebos), the appropriate use of statistics a nd how th e results were reported. Although not for routine use, appl yi ng suc h a scoring system to a group of studies allows a more critical perspective. For exampl e, t he assessment of a group of trials evaluating 5-ASA fo r treatment of ulcerative colitis sh owed that in many cases t he reason studies lost points (had a lowe r rating) was due to t he omission of details of the study design and statistics from t he published report, even though the study was, in most cases, appropriate I y performed ( 4 ) . The message here is that clinical in vestigators can improve the quality of the ir reported t rials by maki ng sure tha t key info rmatio n regarding the design and statistics of their t rial arc included in the manuscript. T he recent move in many fields to apply more clinically orie nted outcome measures to clinical trials is an important step for wards and can only serve to improve their relevance. T he Mc Maste r lnflammacory Bowel Disease Q uestionnaire has been an important advance in the area of infla mmatory bowel d isease (5).
Even with well done clinical trials, we arc often faced with several small negat ive studies or confl icting resu lts hcrwccn studies. How arc we to recon c il e these differences? O ne technique that increasingly is being used is meta-analysis. Metaanalysis is a fo rmal technique of lite ra ture review that allows similar trials to be combined and the results pooled. le is most powerful when the findings of several studies are inconclusive but individua lly lack sufficient power co a nswer a specific question or when stud ies have conflicting resu lts (6, 7) . Although initially developed to be appl iccl to randomized cont rolled trials, methodology is evolving to appl y similar techniques to cohort and case-control stu<lies (8, 9) . The basic featu re of any me ta-analysis is tha t, just like a clinical trial, a fo rmal protocol is followed co answer a specific qucsLion.
Incl usion a nd exclusion c riteria are se t a priori and then applied to a gro up o( studi es. The li terature review must be extensive an<l complete as the findings of missc<l studies can bias the results. A qua lity ana lysis usually is d o ne as pa rrof the analysis. O nce the studies arc selected, the results arc fo rmally cxtractetl and outcome measures determined. The results arc then combined by a varie ty of sratisrical methods. Most of these mctho<ls g ive extra weight to larger studies. O ne c ri t icism o( meta-a nalysis is that it may combine 'apples and oranges'. A lthough the re always will be variation between trials, mcrn-analysis should o nly com bine those studies that arc reasonably s imilar and sho uld highlight any excessive variati on a mo ng the studi es.
When properly applied and executed, meta-ana lysis cc1 n be a powerful cool. As an exam p le, we recently completed a meta-analysis of 5-ASA therapy for acute and mainten ance therapy of ulcerative colitis (1 0). Despite the fact that n o single stutly has d emo nstrated supe ri ori ty of the n ewer 5-ASA prepara tio ns over sulphasalazine, these produc ts have large ly replaced sulphasa laz inc in Canada ; this is assoc iated with a significant increase in cost as most of the newer preparatio ns arc rwo to three times mo re expensive than sulphasalazine. Ou r meta-analys is confirmed that a lthough t he newer 5-ASA produc ts were superi or to placebo, they were me rely equivalent in efficacy to sulphasa lazinc. Given the cost con side rations, it is still reasonable to recommend sulphasalaz ine in the 80% of patients who arc able to to lerate t his medication.
Such a recommentlation can be m ade with greater confide nce based upo n the pooled results of the meta-an alysis than upon any of the single studies. Indeed, it wo uld be d ifficult to m ake such a recommendation based upo n a sing le study with a lo w power of detecting a sma ll d ifference between two simila r drugs.
C linical evaluatio n of inflammato ry bowel d isease remains difficult and ch a lleng ing. It is d iffi cult to predict what the future holds. Novel approaches, such as searc hing for genomes associatctl with inflammatory bowel disease, a rc major undertakings with unclear benefits. Ye t, LO years ago cystic fibrosis had no pote ntia l c ure a nd th erapy was sympto-
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Editoria l matic and palliative. Ide n tification of the cystic fibrosis gene and the potential fo r gen e therapy has made the possibility of a 'cure' fo r cystic fibrosis a reality. Until suc h a 'cure' for infl a mmatory bowel disease is found, the therapeutic questio n s facing us entail compari ng th erapies that are o nly marginally different in terms of efficacy. O u tcome measures beyond disease activity indices will be mo re important in the future. Economic issues must be addressed. Even with rigo rous clinical tria l meth odology, one can antic ipate equ ivocal resul ts as the questions being addressed are increasingly complex. By using the results of o nly well done, clinically applicable trials and applying techniques such as meta-a na lysis when appropri ate, we should be able to better reconcile some of the controversy.
